Enveric Biosciences, Inc. ENVB

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
30/100
Developing

Ranked against 712 peers in Biotechnology

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It … Full ENVB analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.73), suggesting sticky customer base.

Key risks

  • ROIC Below WACC or Peers ROIC at 13.9th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.06), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ENVB ranks in Biotechnology

Enveric Biosciences, Inc. ranks #519 of 713 scored companies in Biotechnology by moat score — the top 73%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
515 Genprex, Inc. GNPX 30/100 Developing
516 Intensity Therapeutics, Inc. INTS 30/100 Developing
517 Mural Oncology plc MURA 30/100 Developing
518 Annovis Bio, Inc. ANVS 30/100 Developing
519 Enveric Biosciences, Inc. ENVB 30/100 Developing
520 Longeveron Inc. LGVN 30/100 Developing
521 Immuneering Corporation IMRX 29/100 Developing
522 AC Immune SA ACIU 29/100 Developing
523 Theriva Biologics, Inc. TOVX 29/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How ENVB scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 73 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 14 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 25 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ENVB's moat

What is Enveric Biosciences, Inc.'s moat score?

Enveric Biosciences, Inc. (ENVB) scores 30 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #519 of 713 scored companies in Biotechnology, the top 73%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (73/100) and its weakest is Capital Efficiency (14/100).

How does Enveric Biosciences, Inc. compare with other Biotechnology companies?

Enveric Biosciences, Inc. ranks #519 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Annovis Bio, Inc. (ANVS) at 30 just above it and Longeveron Inc. (LGVN) at 30 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Enveric Biosciences, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Enveric Biosciences, Inc.?

The Corporate Default template measures 6 defenses, and ENVB scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (73), Capital Efficiency (14), Resilience (25), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000